Gonzalez-Porras, J. R. http://orcid.org/0000-0003-3266-7996
Mateo, J.
Gonzalez-Calle, V.
Marco, P.
Garcia-Gutierrez, V.
Reverter, J. C.
Lecumberri, R.
Article History
Received: 19 August 2021
Accepted: 10 November 2021
First Online: 30 November 2021
Declarations
:
: The authors report no declarations of interest. Financial activities outside the submitted work: Jose Ramon Gonzalez-Porras has received fees for consulting services by Amgen, Novartis, SOBI, Grifols and CSL Behring and speaking honoraria from Novo Nordisk, Shire, SOBI, Roche, Daiichi Sankyo, Pfizer, Rovi, Amgen, and Novartis. Jose Mateo has received speaking honoraria from Leo Pharma and Rovi. Veronica Gonzalez Calle has received research grant from Janssen (Beca SEHH-JANSSEN estancias de formación en el extranjero 2016–2017) and has been a consult for Prothena and Janssen. Pascual Marco has nothing to disclose. Valentin García-Gutierrez has received fees for consulting services by Novartis, BMS, Pfizer and Incyte, has received speaking nonoraria from Novartis, BMS and Pfizer and has received a research funding from Incyte, Celgene, Pfizer, Astellas. Joan Carles Reverter has nothing to disclose. Ramon Lecumberri has received a research grant from Rovi, has received fees for consulting services by Leo Pharma and has received speaking honoraria from Rovi, Leo Pharma, BMS, Sanofi & Daiichi-Sankyo.
: Not applicable for that section.
: Not applicable for that section.
: Not applicable for that section.